PITTSBURGH COMPOUND B UNLABELLED
Demyelinating Disorders
Yale UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Demyelinating Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Interferon ?1 (human fibroblast protein moiety) MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Phase 4 | BB |
METHOTREXATE MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Phase 4 | BB |
ER-176 Mayo Clinic | Phase 2 | CCC |
[ 18f]3f4ap Yale University | Phase 1 | CC |
mk-6240 Yale University | Phase 1 | CC |
[ 18f]3f4ap Yale University | Phase 1 | CC |
Same molecule, other indications
PITTSBURGH COMPOUND B UNLABELLED is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →